# DYSMOTILITY & NUTRITION

## Functional GI disease (<30 types per Rome IV criteria; _Gastro_ 2016;150:1257)

• Recurrent GI sx caused by disorders of gut-brain interaction rather than structural cause

• **Irritable bowel syndrome (IBS)** (_JAMA_ 2015;313:949; _Gastro_ 2015;149:1399 & 2018;154:1140)

Abd discomfort a/w ≥2 of following: improve with defecation, Δ stool frequency, Δ stool form

IBS-C (constipation predominant) vs. **IBS-D** (diarrhea predominant) vs. IBS-M (mixed) vs. IBS-U (unclassified). Sx may be affected by stress, diet, lifestyle, probably microbiome.

**治療:** cog. behavioral Rx, probiotics, exercise, consider gut-brain modulators (eg, TCA, SSRI), Δ diet (↓ fermentable short-chain carbohydrates)

IBS-C: ↑ soluble fiber in diet, laxatives (eg, lubiprostone, linaclotide, PEG), biofeedback

IBS-D: loperamide or rifaximin; eluxadoline, µ & κ agonist, δ antag (_NEJM_ 2016;374:242)

• **Cyclic vomiting syndrome (CVS):** acute recurrent vomiting; a/w marijuana use, personal or FHx of migraine. Acute Rx: antiemetics, IVF, sumatriptan, BZDs; prevention: TCAs/AEDs; avoid marijuana.

## Gastroparesis (_Gastro Clinics of NA_ 2015;44:1; _World J Gastro_ 2015;21:6842)

• Delayed gastric emptying without obstruction, typically 表現為 nausea (>90%), vomiting (>80%), early satiety (60%), postprandial fullness/pain

• Etiol: DM, post-surg, post-viral, crit. illness, Parkinson’s, opiates, CCB, anti-cholin

• Dx: gastric emptying scintigraphy

• 治療: prokinetic agents (metoclopramide or erythromycin), antiemetics for sx; feeding tube if refractory; intrapyloric botox & gastric stimulator experimental

## Paralytic ileus of the colon (Ogilvie’s; _ANZ J Surg_ 2015;85:728) & small bowel

• 定義: loss of intestinal peristalsis in absence of mechanical obstruction

• Abd discomfort & distention, ↓ or absent bowel sounds, ± N/V, hiccups

• Typically in elderly, hospitalized, ill 病人; precipitated by: intra-abd process (surgery, pancreatitis, peritonitis, intestinal ischemia), severe med illness (eg, sepsis), meds (opiates, CCB, anticholin.), metab/endo 異常 (thyroid, DM, kidney failure, liver failure, hypoK), spinal cord compression/trauma, neurologic d/o (Parkinson’s, Alzheimer’s, MS)

• KUB or CT with colonic dilatation (in ileus, dilated loops of SB) without mech obstruction; cecal diam >12 cm a/w high-risk perf in Ogilvie’s

• **治療:** conservative measures (NPO, avoid offending meds) usually effective; IV **neostigmine** (monitor for bradycardia), methylnaltrexone; bowel decompression with NGT, rectal tube. Ogilvie’s only: colonoscopy; if refractory, colostomy or colectomy.

## Constipation (_Annals_ 2015;162:ITC1)

• Defined as dissatisfaction with defecation or (per Rome IV): ≥2 of following during last 3–6 mo ≥25% of the time: straining, lumpy/hard stools, incomplete evacuation, sensation of anorectal obstruction, manual maneuvers to facilitate defecation, stool frequency <3/wk

• **Primary 原因:** slow transit vs. pelvic floor dyssynergia

• **Secondary 原因** (4 Ms)

Mech obstruction: malignancy, compression, rectocele, strictures

Meds: opioids, TCAs, anticholinergics, CCB, NSAIDs, diuretics, Ca2+, Fe

Metabolic/endo: DM, hypothyroid, uremia, preg, panhypopit, porphyria, ↑ Ca, ↓ K, ↓ Mg

Myopathy/Neuro: Parkinson’s, Hirschsprung’s, amyloid, MS, spinal injury, dysautonomia

• **Dx:** H&P with DRE. Labs: consider CBC, electrolytes with Ca, TSH. Colonoscopy if alarm sx. Anorectal manometry/balloon expulsion test; colonic transit study; defecography.

• **治療:** ↑ fluid & fiber intake. Emollient laxative (docusate): softens stool.

Bulk laxatives (psyllium, methylcellulose, polycarbophil): ↑ colonic residue, ↑ peristalsis

Osmotic laxatives (Mg, NaPO4 \[avoid in CKD\], lactulose, PEG): ↑ H2O in colon

Stimulant laxatives (senna, castor oil, bisacodyl): ↑ motility & secretion

Enema/suppository (phosphate, mineral oil, tap water, soapsuds, bisacodyl)

Lubiprostone (↑ secretion); methylnaltrexone and alvimopan for opioid-induced

Plecanitide (cGMP agonist) for chronic idiopathic constipation (_Gastroenterol_ 2016;150:S317)

Linaclotide ↑ stool freq, ↓ straining/bloating (_Am J Gastro_ 2018;113:105)

## Nutrition in critical illness (also see “Mech Ventilation”) (_Crit Care_ 2015;19:35)

• Enteral & parenteral with similar 臨床outcomes (_Lancet_ 2018;391:133)

• **Enteral** (EN): starting within 48–72 hr of ICU admit may ↓ infxn & mort, but repletion of 100% caloric needs may be harmful (_Cochrane_ CD0078767). Contraindic. if obstruction, major GIB. Possible complic: ischemic bowel b/c ↑ demand for splanchnic blood; aspiration PNA.

• **Parenteral** (PN): start after 7 d if unable to tolerate enteral feeds, late (> day 8 of ICU stay) Contraindic: hyperosmolality, severe electrolyte disturbances, severe hyperglycemia; sepsis is _relative_ contraindication. Complications: hyperglycemia (due to dextrose), catheter sepsis/thrombus, refeeding syndrome, LFT 異常 (steatosis, cholestasis, gallbladder sludge due to lack of enteric stimulation).
